(J Am Heart Assoc. 2017;6:e005396 DOI:[10.1161/JAHA.116.005396](10.1161/JAHA.116.005396).)28476874

Introduction {#jah32156-sec-0004}
============

Therapeutic advances in chest radiotherapy (XRT) over the past 50 years have dramatically improved survival in patients with thoracic malignancy. Increased longevity, however, is associated with the appearance of late effects of chest (especially mediastinal) XRT, otherwise known as radiation‐associated cardiac disease.[1](#jah32156-bib-0001){ref-type="ref"}, [2](#jah32156-bib-0002){ref-type="ref"}, [3](#jah32156-bib-0003){ref-type="ref"}, [4](#jah32156-bib-0004){ref-type="ref"}, [5](#jah32156-bib-0005){ref-type="ref"} This is a heterogeneous cardiovascular disorder, which covers a broad spectrum of cardiovascular disease processes and may involve any cardiac structure, including the pericardium, myocardium, valvular system, conduction system, and coronary arteries.[1](#jah32156-bib-0001){ref-type="ref"}, [2](#jah32156-bib-0002){ref-type="ref"}, [3](#jah32156-bib-0003){ref-type="ref"}, [4](#jah32156-bib-0004){ref-type="ref"}, [5](#jah32156-bib-0005){ref-type="ref"} The lungs, great vessels, and carotid arteries may also be involved.

Valvular heart disease occurs in as many as 81% of patients with previous mediastinal XRT, with the aortic and mitral valves most commonly affected.[6](#jah32156-bib-0006){ref-type="ref"} Radiation‐associated valvular disease has a varied spectrum with progressive thickening and calcification of the affected valves and resultant progressive stenosis and/or regurgitation. A substantial proportion of such patients develop severe symptomatic valvular (including aortic stenosis \[AS\]) disease requiring cardiovascular surgery. However, a recent study from our group found significantly increased long‐term mortality among all patients with prior radiation undergoing open heart surgery.[7](#jah32156-bib-0007){ref-type="ref"} This may be attributed to the presence of multiple cardiac lesions, primary myocardial/pericardial dysfunction, pulmonary and vascular comorbidities, and XRT‐induced fibrosis of lungs and surrounding tissues, all of which result in a hostile surgical environment. With the emergence of percutaneous technologies, there has been a heightened emphasis on elucidating outcomes in patients with radiation‐associated AS undergoing surgical aortic valve (AV) replacement (SAVR). In this study, we sought to: (1) study long‐term survival in patients with mediastinal XRT‐associated severe AS undergoing SAVR and compare these patients with a matched cohort undergoing SAVR during the same time frame; and (2) to identify potential predictors of long‐term mortality.

Methods {#jah32156-sec-0005}
=======

This was an observational cohort study (matched design) of patients with severe AS who underwent SAVR at our tertiary care referral center between January 1, 2000 and January 1, 2015. The study population consisted of two equally matched groups (an "XRT group" and a "comparison group"). The XRT group consisted of 172 symptomatic patients with a history of thoracic malignancy who underwent mediastinal irradiation and consequently developed AS severe enough to require SAVR. The diagnosis of radiation‐associated AS was made after a thorough clinical and echocardiographic evaluation by experienced cardiologists. The type of malignancy and the year of radiation were all documented, where available. The comparison group consisted of 172 symptomatic patients without a history of thoracic malignancy or prior chest/mediastinal irradiation who were 1:1 matched in terms of age (within 2 years), sex, type and timing of AV replacement (AVR; within 2 years), and AV area (within 0.1 cm^2^). The comparison group was identified from \>10 000 patients who underwent SAVR during the same time frame. We excluded patients with significant multivalvular disease, documented constrictive pericarditis, and severe restrictive lung disease. However, in our contemporary experience of AS patients, concomitant coronary artery disease (CAD) is common and, as a result, we decided to include this subgroup.[8](#jah32156-bib-0008){ref-type="ref"} All procedures were elective and none were performed in an emergent/urgent setting.

Data were assembled through individual analysis of electronic medical records after obtaining appropriate institutional review board approval with waiver of individual informed consent. Clinical data and demographics were recorded prospectively in the electronic medical records at the time of initial clinical encounter and manually extracted for the current study. Baseline patient characteristics including demographics, symptoms, vital signs, medical history, oncologic history, and common laboratory and pulmonary function test values before SAVR were collected. Data were obtained as close to the date of SAVR as possible (within 1 month in the majority of cases). Medication use at the time of SAVR was ascertained by electronic medical record review. Based on the above data, the Society of Thoracic Surgeons (STS) score and Charlson comorbidity index were calculated. Even though the STS score has only been validated to predict 30‐day postoperative mortality, we used it in the survival analysis, as it is a composite of many factors that are known to be associated with adverse postoperative events in the longer‐term in AS patients.[8](#jah32156-bib-0008){ref-type="ref"} In addition, we calculated Charlson comorbidity index in all patients, as a surrogate for frailty and comorbidity.[9](#jah32156-bib-0009){ref-type="ref"} All patients were deemed free of any major comorbid condition such as recurrence of original tumor or subsequent development of a new tumor and cleared to undergo cardiac surgery after a thorough clinical evaluation by cardiology and cardiothoracic surgery.

Preoperative Echocardiography and Additional Imaging {#jah32156-sec-0006}
----------------------------------------------------

All patients underwent a comprehensive echocardiogram with commercially available instruments (Philips Medical Systems, NA, Bothell, WA; General Electric Medical Systems, Milwaukee, WI; and Siemens Medical Solutions USA, Inc, Malvern, PA) as part of a standard clinical diagnostic evaluation. Measurements and recordings were obtained according to current recommendations.[10](#jah32156-bib-0010){ref-type="ref"}, [11](#jah32156-bib-0011){ref-type="ref"} Left ventricular ejection fraction was calculated using the Simpson\'s biplane method. We used a semiquantitative 5‐point scale (with grades of none, mild, moderate, moderately severe, and severe) to stratify valvular regurgitation on color 2‐dimensional Doppler echocardiography clips obtained in multiple standard views. Right ventricular systolic pressure was estimated in a standard fashion.[12](#jah32156-bib-0012){ref-type="ref"}

For quantification of AS severity, LV outflow tract (LVOT) diameter was measured in a standard fashion on parasternal long‐axis views and the AV area was calculated using the continuity equation, according to guidelines.[11](#jah32156-bib-0011){ref-type="ref"} Severe AS was defined as AV area ≤1 cm^2^. LV stroke volume index (LV‐SVI) was measured using the following formula: LVOT~VTI~×LVOT~area~/body surface area. A cutoff ≥35 mL/m^2^ was considered as preserved LV‐SVI.[11](#jah32156-bib-0011){ref-type="ref"}, [13](#jah32156-bib-0013){ref-type="ref"}, [14](#jah32156-bib-0014){ref-type="ref"}, [15](#jah32156-bib-0015){ref-type="ref"}

Where available, data on the degree of ascending aortic calcification assessed on chest multidetector computed tomography were recorded. In patients with a history of cardiac surgery, preoperative planning using computed tomography was performed, as previously described.[16](#jah32156-bib-0016){ref-type="ref"}

Surgery {#jah32156-sec-0007}
-------

The details of various surgical therapies for management of AS were recorded and categorized as follows[8](#jah32156-bib-0008){ref-type="ref"}: (1) AVR, (2) AVR and coronary artery bypass grafting (CABG), and (3) AVR and other (concomitant aortic surgery). The type of valvular prosthesis (mechanical versus bioprosthesis) was recorded. The use of internal mammary artery was also recorded. Because chest and mediastinal XRT can potentially damage the internal mammary arteries, they were reviewed on preoperative coronary angiography and only the arteries that were deemed suitable were used. The final decision regarding the specific operative technique was made by the attending cardiothoracic surgeon. In patients with high‐risk features (eg, significant ascending aortic calcification, redo surgery), preventive surgical strategies were employed.[17](#jah32156-bib-0017){ref-type="ref"}

Follow‐Up {#jah32156-sec-0008}
---------

The beginning of follow‐up was considered the date of AVR. Postoperative data, including the length of intensive care unit and hospital stay and postoperative complications such as pericardial effusion, arrhythmia, stroke, and myocardial infarction, were recorded. The primary end point was all‐cause mortality. Data on death and survival were obtained from the medical record, from the US Social Security Death Index, or the Ohio Death Index. We attempted to ascertain the cause of death from chart review or telephone follow‐up. Cardiovascular mortality was defined as any death due to cardiac arrest, myocardial infarction, arrhythmia, heart failure, or any other cardiovascular cause. In addition, if the cause of death could not be discerned, this was also categorized as cardiovascular in etiology unless the patient\'s proximal history strongly suggested a noncardiovascular cause.[18](#jah32156-bib-0018){ref-type="ref"}

Statistical Analysis {#jah32156-sec-0009}
--------------------

Continuous variables were expressed as mean±SD or median. When appropriate, continuous variables were also divided into 2 groups based on median for further analyses. Categorical data are presented as percentage frequency. Differences in baseline and procedural characteristics between matched groups were assessed with Student paired *t* test or repeated‐measures ANOVA (for parametric variables) and the Wilcoxon signed‐rank test (for nonparametric variables). Differences in the distribution of categorical variables were compared using conditional logistic regression stratified by matched pair. Cox proportional hazards analysis was performed to determine the association of relevant predictors with mortality. Multivariable analysis ignoring matched pairs was performed to describe the impact of the matched variables and mediastinal XRT exposure on mortality. Subsequently, conditional Cox proportional hazards stratified by matched pair was performed to discern whether prior mediastinal XRT exposure remained an independent predictor of mortality.[19](#jah32156-bib-0019){ref-type="ref"} Multivariable models for mortality were built using variables thought to be most biologically important to the outcome, avoiding colinearity and overfitting (a 10 event to 1 variable ratio was used). Cox proportional hazard results are reported as hazard ratios (HRs) with 95% CIs. Cumulative survival probabilities as a function of time were obtained via the Kaplan--Meier method, and event curves were compared using the log‐rank test. Significance was determined at *P*\<0.05. Statistical analysis was performed with R version 3.1.0 and SPSS version 11.5 (SPSS Inc, Chicago, IL).

Results {#jah32156-sec-0010}
=======

The clinical and echocardiographic characteristics of our matched study cohort are shown in Table [1](#jah32156-tbl-0001){ref-type="table-wrap"}. Due to the fact that the primary study population had a history of mediastinal XRT, they were relatively younger as compared with a standard population who develop severe AS requiring SAVR. The 2 groups were well matched in terms of the incidence of standard risk factors and obstructive CAD; however, as would be expected, the proportion of patients with significant left main and 3‐vessel CAD was higher in the XRT group. Similarly, results from pulmonary function tests were slightly worse in the XRT patients versus controls, as would be expected. While AV area and left ventricular ejection fraction were similar in both groups, peak and mean AV gradients were higher and the proportion of patients with an abnormal LV‐SVI was higher in the XRT group. On the other hand, the STS score and Charlson comorbidity index were similar in the 2 groups. A multidetector computed tomography scan was performed in all 172 patients in the XRT group versus 109 patients in the control group. Significant (at least partially circumferential) calcification of the ascending aorta was observed in 62 (36%) patients in the XRT group versus none in the control group (*P*\<0.001).

###### 

Baseline Characteristics of the Matched Study Cohort

  Variable                                           XRT Group (n=172)   Comparison Group (n=172)   *P* Value
  -------------------------------------------------- ------------------- -------------------------- -----------
  Clinical, demographic, and symptom variables                                                      
  Age, y                                             63±13               64±13                      N/A
  Female sex                                         106 (62)            106 (62)                   N/A
  Hypertension                                       105 (61)            119 (69)                   0.073
  Diabetes mellitus                                  35 (20)             44 (26)                    0.154
  Hyperlipidemia                                     104 (61)            110 (64)                   0.291
  Obstructive CAD                                    45 (26)             47 (27)                    0.457
  ≥50% left main or 3‐vessel CAD                     40 (23)             8 (5)                      \<0.001
  Atrial fibrillation                                9 (5)               13 (8)                     0.263
  End‐stage renal disease                            2 (1)               1 (0.6)                    0.502
  Smoking history                                    76 (44)             70 (40)                    0.496
  Prior stroke                                       14 (8)              15 (9)                     0.502
  Prior cardiac surgery                              34 (20)             29 (17)                    0.492
  Dyspnea on exertion                                161 (94)            153 (89)                   0.243
  Angina                                             53 (31)             56 (33)                    0.412
  Syncope                                            11 (6)              8 (5)                      0.319
  Median STS score with interquartile range, %       4 \[2--13\]         4 \[3--11\]                0.323
  Charlson comorbidity index                         3.3±1.6             3.1±1.5                    0.311
  Medications                                                                                       
  Betablockers                                       105 (61)            98 (57)                    0.24
  Statins                                            102 (60)            81 (47)                    0.02
  Angiotensin‐converting enzyme inhibitors           32 (19)             43 (25)                    0.10
  Aspirin                                            100 (59)            96 (56)                    0.35
  Laboratory and pulmonary function data                                                            
  Glomerular filtration rate, mL/min per 1.73 m^2^   74±24               77±23                      0.168
  Hemoglobin, mg/dL                                  13.2±02             13.1±2                     0.209
  FEV~1~ (% of predicted)                            74±14               70±16                      0.018
  FVC (% of predicted)                               78±13               74±16                      0.026
  FEV~1~/FVC ratio                                   94±9                94±8                       0.502
  Echocardiographic data                                                                            
  Left ventricular ejection fraction, %              54±11               56±9                       0.049
  Aortic valve area, cm^2^                           0.73±0.21           0.70±0.14                  N/A
  Peak aortic valve gradient, mm Hg                  64±25               85±22                      \<0.001
  Mean aortic valve gradient, mm Hg                  39±11               49±13                      \<0.001
  LV‐SVI                                             38±14               40±11                      0.224
  Abnormal LV‐SVI (\<35 mL/m^2^)                     89 (52)             61 (35)                    \<0.001
  Aortic regurgitation (≥II+)                        16 (9)              17 (10)                    0.842
  Right ventricular systolic pressure, mm Hg         39±11               37±10                      0.113

Values are expressed as number (percentage) or mean±SD.

Because the prior chest radiotherapy exposure (XRT) and comparison groups were matched based on age, sex, and aortic valve area, *P* values are not reported. CAD indicates coronary artery disease; FEV~1~, forced expiratory volume at 1 second; FVC, forced vital capacity; LV‐SVI, left ventricular stroke volume index; N/A, not applicable; STS, Society of Thoracic Surgeons.

The breakdown of surgeries in the entire cohort was as follows: isolated SAVR (n=134 \[39%\]), SAVR+CABG (n=92 \[27%\]), and SAVR+aorta (n=118 \[34%\]), with no differences between subgroups, by study design. Within the CABG group, internal mammary artery was utilized in 71 cases, with a significantly lower proportion of use in the XRT versus the control group (27 versus 44, *P*\<0.01). The number of utilized coronary bypass grafts were significantly higher in the XRT versus control groups (1.8±1.2 versus 1.2±0.9, *P*\<0.05). A significantly higher proportion of XRT patients needed hypothermic circulatory arrest versus the control patients (48 patients versus 9 patients, *P*\<0.001).

The breakdown of prior malignancies and radiation doses in the XRT group was as follows: breast cancer (51 \[30%\], 50--60 Gy), lung cancer with mediastinal involvement (5 \[3%\], 60 Gy), Hodgkin\'s lymphoma (94 \[55%\], 40--45 Gy), non‐Hodgkin\'s lymphoma (10 \[6%\], 40--45 Gy), and others, including esophageal cancer (12 \[7%\], 40--45 Gy). The median time from XRT to surgery was 25 \[18--32\] years and 31 (18%) patients had received prior chemotherapy.

Outcomes {#jah32156-sec-0011}
--------

The immediate postoperative outcomes for both groups are demonstrated in Table [2](#jah32156-tbl-0002){ref-type="table-wrap"}. During surgery, mediastinal adhesions were observed in all XRT patients, while they were observed only in redo surgical cases in the control group (100% versus 17%, *P*\<0.001). As expected, the cardiopulmonary bypass time (96±25 minutes versus 80±12 minutes) and total procedure time (incision to skin closure time, 233±40 minutes versus 175±35 minutes) were significantly higher in the XRT versus the control group (both *P*\<0.001). While the majority of patients in the entire study cohort had a bioprosthetic AVR implanted, a significantly higher proportion of XRT patients had a mechanical valve implanted. As expected, patients in the XRT group had a longer intensive care unit and in‐hospital stay, a higher rate of readmission within the first 3 months postoperatively, and a higher rate of postoperative and permanent atrial fibrillation versus the comparison group. In addition, 10 patients had in‐hospital postoperative stroke (9 in the XRT and 1 in the comparison group, respectively; *P*=0.01), while 4 (2.3%) patients died during hospitalization for the procedure (all in the XRT group and none in the comparison group, *P*=0.01).

###### 

Perioperative and Postoperative Characteristics of the Matched Study Cohort

  Variable                                                      XRT Group (n=172)   Comparison Group (n=172)   *P* Value
  ------------------------------------------------------------- ------------------- -------------------------- -----------
  Type of aortic valve replacement                                                                             
  Bioprosthesis                                                 137 (80)            157 (91)                   \<0.001
  Mechanical                                                    35 (20)             15 (9)                     
  Perioperative blood transfusions, No. of units                3.1±1.6             2±1.2                      \<0.001
  Perioperative inotropic support                               74 (43)             58 (34)                    0.03
  Length of hospital stay                                       15±13               9±6                        \<0.001
  Length of intensive care unit stay                            5±9                 2±3                        \<0.001
  ≥Moderate pericardial effusion                                51 (30)             42 (24)                    0.274
  Cardiac tamponade                                             1 (1)               0                          0.521
  In‐hospital myocardial infarction                             0                   1 (1)                      0.502
  In‐hospital stroke                                            9 (5)               1 (1)                      0.005
  In‐hospital mortality                                         4 (2)               0                          0.005
  In‐hospital atrial fibrillation                               86 (50)             52 (30)                    \<0.001
  Persistent postoperative atrial fibrillation                  49 (29)             24 (14)                    \<0.001
  Permanent pacemaker                                           18 (11)             8 (5)                      0.005
  Internal defibrillator                                        1 (1)               1 (1)                      0.504
  Left ventricular ejection fraction, %                         52±9                53±5                       0.114
  Recurrent admission following initial discharge within 3 mo   37 (22)             14 (8)                     \<0.001

Values are expressed as number (percentage) or mean±SD.

XRT indicates prior chest radiotherapy exposure.

During a mean follow‐up of 5.7±3 years, there were 95 (28%) deaths in the total cohort, with a significantly higher proportion of events in the XRT group versus the comparison group (83 of 172 \[48%\] versus 12 of 172 \[7%\], *P*\<0.001). Kaplan--Meier curves comparing the mortality between the XRT and comparison groups are shown in Figure [1](#jah32156-fig-0001){ref-type="fig"} (Log‐rank statistic 89, *P*\<0.001). Within the XRT group, only 9 patients died due to a documented noncardiac etiology (1 due to recurrent cancer, 1 due to septic shock, and 7 due to multiorgan failure). The remainder had a cardiorespiratory or unknown etiology (specifically, none of these patients had a documented noncardiac disorder, including malignancy, recognized before death that would be deemed as a cause of death). No patient in the comparison group had a noncardiac etiology to account for death.

![Kaplan--Meier survival curves of the entire study cohort separated into 2 subgroups: mediastinal radiotherapy (XRT group) vs the comparison group.](JAH3-6-e005396-g001){#jah32156-fig-0001}

We performed univariable Cox proportional hazard analyses in the whole study cohort to identify potential variables associated with increased mortality. The results are shown in Table [3](#jah32156-tbl-0003){ref-type="table-wrap"}. Incorporating relevant univariable predictors, we subsequently performed multivariable Cox proportional hazard analyses in the whole study cohort, the results of which are shown in Table [4](#jah32156-tbl-0004){ref-type="table-wrap"}. Prior mediastinal XRT exposure (HR, 8.51; 95% CI, 4.46--16.23) and higher STS score (HR, 1.13; 95% CI, 1.03--1.26) were the only significant factors associated with higher longer‐term mortality (both *P*\<0.001).

###### 

Univariable Cox Proportional Hazards Analysis for the Primary End Point of All‐Cause Mortality

  Variable                                                Hazard Ratio (95% CI)   Chi‐Square   *P* Value
  ------------------------------------------------------- ----------------------- ------------ -----------
  Preoperative characteristics                                                                 
  Prior XRT exposure                                      11.00 (5.89--20.53)     59.2         \<0.001
  Age (for 10‐year increase)                              1.45 (1.23--1.70)       20.1         \<0.001
  Female sex                                              1.34 (0.86--2.09)       1.8          0.178
  Hypertension                                            1.09 (0.70--1.70)       0.17         0.682
  Diabetes mellitus                                       1.04 (0.64--1.68)       0.03         0.857
  Hyperlipidemia                                          1.05 (0.69--1.60)       0.05         0.823
  Obstructive CAD                                         1.58 (1.32--1.89)       22.9         \<0.001
  ≥50% left main or ≥70% 3‐vessel CAD                     4.10 (2.23--7.51)       21.7         \<0.001
  Atrial fibrillation                                     1.64 (0.64--4.23)       1.1          0.291
  Smoking history                                         1.03 (0.61--1.72)       0.02         0.923
  Prior stroke                                            1.08 (0.55--2.13)       0.05         0.818
  Type of prior cancer (lymphoma vs other)                1.24 (0.98--1.98)       2.4          0.092
  Prior cardiac surgery                                   3.22 (2.07--5.01)       27.9         \<0.001
  Glomerular filtration rate (for every unit reduction)   1.04 (1.01--1.07)       4.1          0.033
  FEV~1~ (for every unit reduction)                       1.02 (1.01--1.03)       11.6         0.005
  FVC (for every unit reduction)                          1.02 (1.01--1.03)       11.2         0.006
  FEV~1~/FVC ratio                                        1.02 (1.01--1.03)       4.5          0.009
  STS score (for every 1% increase)                       1.22 (1.11--1.35)       15.2         \<0.001
  Charlson comorbidity index                              1.23 (1.09--1.39)       13.9         \<0.001
  β‐Blockers                                              0.75 (0.48--1.16)       0.17         0.192
  Statins                                                 0.96 (0.63--1.46)       0.03         0.864
  Angiotensin‐converting enzyme inhibitors                0.84 (0.52--1.35)       0.57         0.448
  Aspirin                                                 0.93 (0.61--1.42)       0.12         0.732
  LVEF (for every 10% reduction)                          1.22 (1.02--1.46)       4.7          0.029
  Abnormal vs normal LV‐SVI                               1.68 (1.11--2.54)       6.3          0.013
  Aortic valve area (for every 0.1 cm^2^ worsening)       1.87 (0.61--3.75)       1.3          0.263
  Operative and postoperative characteristics                                                  
  Extent of cardiac surgery                                                                    
  Isolated AVR                                            Reference                            
  AVR+CABG                                                3.67 (2.08--6.49)       21           \<0.001
  AVR+aorta                                               2.25 (0.78--2.00)       0.91         0.233
  Use of internal mammary artery vs not                   1.09 (0.51--4.13)       0.14         0.862
  Cardiopulmonary bypass time                             1.12 (0.62--1.59)       0.20         0.582
  Perioperative inotropic support vs not                  1.74 (0.84--3.18)       1.6          0.189
  No. of units of perioperative blood transfusions        1.07 (0.53--1.83)       0.15         0.722
  Bioprosthetic vs mechanical AVR                         1.31 (0.74--2.32)       0.92         0.341
  Persistent postoperative atrial fibrillation            2.03 (1.30--3.18)       10.2         \<0.001
  Permanent pacemaker                                     1.66 (0.83--3.51)       2.07         0.148
  Postoperative LVEF (for every 10% reduction)            1.10 (0.72--1.69)       0.19         0.612

AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; CAD, coronary artery disease; FEV~1~, forced expiratory volume at 1 second; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; LV‐SVI, left ventricular stroke volume index; STS, Society of Thoracic Surgeons; XRT, chest radiotherapy.

###### 

Multivariable Cox Proportional Hazards Analysis for the Primary End Point of All‐Cause Mortality

  Variable                                                Hazard Ratio (CI)    Chi‐Square   *P* Value
  ------------------------------------------------------- -------------------- ------------ -----------
  Prior XRT exposure                                      8.12 (4.26--15.64)   44.7         \<0.001
  STS score (for every 1% increase)                       1.14 (1.03--1.26)    7.0          0.008
  Abnormal vs normal LV‐SVI                               1.33 (0.86--2.04)    1.72         0.19
  FEV~1~ (for every unit decrease)                        1.01 (0.99--1.03)    1.2          0.28
  Extent of cardiac surgery                                                                 
  Isolated AVR                                            Reference                         
  AVR+CABG                                                1.71 (0.94--3.11)    3.2          0.07
  AVR+aorta                                               1.13 (0.70--1.84)    0.19         0.65
  Persistent postoperative atrial fibrillation            1.22 (0.76--1.95)    0.70         0.40
  Chi‐square for the overall model was 110 (*P*\<0.001)                                     

The model does not account for matching. Please see text for results from the matched model. Predictors that constitute the Society of Thoracic Surgeons (STS) score were not individually entered into the analysis. When forced vital capacity (FVC) or forced expiratory volume at 1 second (FEV~1~)/FVC ratio were entered instead of FEV~1~, the results were similar. Due to collinearity between the Charlson comorbidity index and STS score, only the STS score was entered. Results were similar if the Charlson comorbidity index was entered instead of the STS score. AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; LV‐SVI, left ventricular stroke volume index; XRT, chest radiotherapy.

Differences in mortality were further compared among subgroups. As shown in Table [5](#jah32156-tbl-0005){ref-type="table-wrap"}, within all subgroups, the proportion of deaths were significantly higher in the XRT versus the comparison group. Specifically, 82% of the patients undergoing redo cardiac surgery in the XRT group died during long‐term follow‐up. In addition, the mortality in the XRT group was significantly higher than the comparison group, even when the patients were further stratified based on STS score higher or lower than a median of 4%. The Kaplan--Meier curves of the entire study cohort, separated into 4 subgroups (XRT versus comparison and STS score higher or lower than median) are shown in Figure [2](#jah32156-fig-0002){ref-type="fig"} (log‐rank statistic 95, *P*\<0.001).

###### 

Long‐Term All‐Cause Mortality Stratified by Prior XRT Exposure, Separated by Relevant Subgroups

  Variable                                        XRT Group (n=172)   Comparison Group (n=172)
  ----------------------------------------------- ------------------- --------------------------
  Age, median 65 y                                                    
  \<65 y                                          34/92 (37)          0/83
  ≥65 y                                           49/80 (61)          12/89 (14)
  Sex                                                                 
  Male                                            28/66 (42)          2/66 (3)
  Female                                          35/106 (33)         10/106 (9)
  Obstructive coronary artery disease                                 
  Yes                                             57/127 (45)         7/125 (6)
  No                                              26/45 (58)          5/47 (11)
  Left ventricular stroke volume index                                
  \<35 mL/m^2^                                    46/89 (52)          6/61 (10)
  ≥35 mL/m^2^                                     37/83 (45)          6/111 (5)
  Society of Thoracic Surgeons score, median 4%                       
  \<4%                                            30/78 (39)          0/91
  ≥4%                                             53/94 (56)          12/81 (15)
  Surgery                                                             
  AVR                                             10/40 (25)          7/94 (7)
  AVR+CABG                                        26/45 (58)          5/47 (11)
  AVR+aorta                                       47/87 (54)          0/91
  Redo cardiac surgery                                                
  No                                              54/138 (39)         9/143 (6)
  Yes                                             28/34 (82)          3/29 (10)
  AVR type                                                            
  Bioprosthetic                                   71/127 (52)         12/157 (8)
  Mechanical                                      12/35 (34)          0/15
  Permanent postoperative atrial fibrillation                         
  No                                              55/123 (45)         10/148 (7)
  Yes                                             28/49 (57)          2/24 (8)

All differences between subgroups were significant (*P*\<0.001), derived from univariable Cox proportional hazard analysis, shown in Table [3](#jah32156-tbl-0003){ref-type="table-wrap"}. Values are expressed as number (percentage) AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; XRT, chest radiotherapy.

![Kaplan--Meier survival curves of the entire study cohort separated into 4 subgroups, based on mediastinal radiotherapy (XRT) vs not and Society of Thoracic Surgeons (STS) score better or worse than median.](JAH3-6-e005396-g002){#jah32156-fig-0002}

To account for matching status, a multivariable conditional Cox proportional hazards model was also built stratified by matched group. This model was adjusted for mediastinal XRT exposure, STS score, type of cardiac surgery, permanent postoperative atrial fibrillation, and forced expiratory volume at 1 second. Again, prior XRT exposure (HR, 4.21; 95% CI, 2.24--7.85) and higher STS score (HR, 1.07; 95% CI, 1.01--1.17) had a significant association with all‐cause mortality (both *P*\<0.01).

Finally, in order to remove the potentially incremental deleterious impact of obstructive CAD on long‐term survival, we excluded patients who underwent concurrent CABG. In that subgroup (n=252, 64 deaths, follow‐up 6±3 years), multivariable Cox survival analysis also demonstrated that higher STS score (HR, 1.12; 95% CI, 1.02--1.33) and prior mediastinal XRT exposure (HR, 9.94; 95% CI, 4.84--22.3) were associated with increased long‐term mortality (*P*\<0.01). A significantly higher proportion (*P*\<0.001) of patients in the XRT group died as compared with the comparison group: 57 of 125 (46%) versus 7 of 125 (6%). The Kaplan--Meier survival curves for this subgroup of patients are shown in Figure [3](#jah32156-fig-0003){ref-type="fig"} (log‐rank statistic 61, *P*\<0.001).

![Kaplan--Meier survival curves of the subgroup without obstructive coronary artery disease separated into 2 subgroups: mediastinal radiotherapy (XRT group) vs comparison group.](JAH3-6-e005396-g003){#jah32156-fig-0003}

Discussion {#jah32156-sec-0012}
==========

In the current study of patients with symptomatic severe AS undergoing SAVR, we demonstrate that patients with mediastinal radiation--associated severe AS (XRT group) have significantly worse longer‐term survival versus an age‐ and sex‐matched comparison group undergoing similar procedures around the same time frame. The majority of the deaths in the XRT group were due to cardiopulmonary disease or multiorgan failure, rather than recurrent malignancies. There were multiple factors associated with higher longer‐term mortality on univariable analysis, including abnormal LV‐SVI (suggesting a higher proportion of impaired contractile reserve) and abnormal findings on pulmonary function tests. However, on multivariable survival analysis, higher STS score and prior mediastinal XRT exposure were the only 2 factors independently associated with increased longer‐term mortality. In patients with radiation heart disease, standard risk stratification fares poorly for longer‐term outcomes and additional specific factors need to be considered. In addition, the finding of poor survival in the XRT group was similar when patients with obstructive CAD were excluded from the analysis (Figure [3](#jah32156-fig-0003){ref-type="fig"}).

Although long‐term survival was dramatically worse in the radiation group, there was no such difference in short‐term survival (although the current study may be underpowered to make conclusive assertions about short‐term survival). The perioperative stroke rate was significantly higher in the XRT versus the comparison group, likely due to a higher rate of significant ascending aortic calcification. As expected, immediately following SAVR, patients in the XRT group had significantly greater need for transfusion and inotropic support, along with longer intensive care unit and in‐hospital stay versus the comparison group. However, in spite of a median STS score of 4%, the in‐hospital mortality in the XRT group was only 2.3% (and 0% in the comparison group). However, XRT patients had a higher rate of recurrent admissions following perioperative discharge, due to recurrent heart failure and pleural effusions and a higher rate of permanent atrial fibrillation.

Findings from studies of long‐term outcomes (with or without cardiac surgery) in radiation heart disease patients are limited but do in fact demonstrate increased morbidity and mortality.[1](#jah32156-bib-0001){ref-type="ref"}, [2](#jah32156-bib-0002){ref-type="ref"}, [3](#jah32156-bib-0003){ref-type="ref"}, [4](#jah32156-bib-0004){ref-type="ref"}, [5](#jah32156-bib-0005){ref-type="ref"}, [20](#jah32156-bib-0020){ref-type="ref"}, [21](#jah32156-bib-0021){ref-type="ref"}, [22](#jah32156-bib-0022){ref-type="ref"} Previous surgical reports have demonstrated various predictors of short‐term (constrictive pericarditis, reduced preoperative ejection fraction, longer cardiopulmonary bypass times) and long‐term outcomes (radiation dose, duration of radiation, tangential versus mediastinal).[4](#jah32156-bib-0004){ref-type="ref"}, [20](#jah32156-bib-0020){ref-type="ref"}, [22](#jah32156-bib-0022){ref-type="ref"}, [23](#jah32156-bib-0023){ref-type="ref"} However, many of these studies had significantly smaller sample sizes and patients with complex surgeries (eg, CABG plus valve procedures) were excluded. We previously demonstrated that prior XRT exposure was an independent risk factor for increased long‐term mortality in patients undergoing cardiac surgery, including isolated CABG as well as combined CABG and valvular surgery.[7](#jah32156-bib-0007){ref-type="ref"} We have also reported that certain features may be potential predictors of adverse outcomes in patients with radiation‐associated cardiac disease, including abnormally thickened aortomitral curtain, reduced left ventricular global longitudinal strain, and worse degree of pulmonary fibrosis.[7](#jah32156-bib-0007){ref-type="ref"}, [24](#jah32156-bib-0024){ref-type="ref"}, [25](#jah32156-bib-0025){ref-type="ref"}, [26](#jah32156-bib-0026){ref-type="ref"}

To the best of our knowledge, the current study is one of the largest to assess long‐term survival in patients with XRT‐associated severe AS undergoing SAVR and to compare them with a matched population. Although our data on cause of death after surgery in the radiation group are limited, it appears that cardiopulmonary disease was a common mechanism of death. This is likely because of the possibility that prior chest (especially mediastinal) XRT exposure introduces multiple technical problems at the time of surgery due to radiation‐induced fibrosis of surrounding tissues, adhesions, and the presence of multiple cardiac lesions.[24](#jah32156-bib-0024){ref-type="ref"} Radiation patients frequently develop pulmonary complications as a result of open heart surgery, not the least of which are recurrent pleural effusions and severe restrictive lung disease. It is our experience that respiratory complications may significantly compromise function and survival in patients with extensive prior radiation. In addition, the presence of myocardial disease either as a result of the underlying cardiac condition (potentially exacerbated by prior concomitant chemotherapy) or as a consequence of a restrictive‐type cardiomyopathy produced by the effects of radiation may play a role in impaired survival and is not necessarily improved by valvular surgery. Indeed, abnormal LV‐SVI was more frequently observed in the XRT group, despite similar left ventricular ejection fraction (likely suggesting more intrinsic myocardial disease).

The results of the current study raise the following question: Could patients who develop severe AS in the setting of a prior history of mediastinal XRT be best served by newer nonsurgical therapies such as transcatheter AVR? While promising trends in short‐ and intermediate‐term survival with transcatheter AVR have been noted in nonradiation cohorts at intermediate and high surgical risk,[27](#jah32156-bib-0027){ref-type="ref"}, [28](#jah32156-bib-0028){ref-type="ref"}, [29](#jah32156-bib-0029){ref-type="ref"} robust data on long‐term outcomes in patients with heart disease after radiation who have undergone transcatheter AVR are currently lacking. Indeed, an automatic assumption that a percutaneous approach in patients with heart disease after radiation would be better needs to be made with caution. In a recent report, we have demonstrated that patients who develop obstructive CAD due to prior XRT exposure and subsequently undergo percutaneous coronary intervention had high mortality compared with a matched control population.[19](#jah32156-bib-0019){ref-type="ref"} Another therapeutic consideration is heart transplantation or heart‐lung transplantation in selected patients with evidence of significant myocardial disease that appears disproportionate to the coronary or valvular issues or in whom there is significant restrictive lung disease. However, heart or heart‐lung transplantation in this group has significant associated concerns. Recurrent malignancy may be more common after graft‐versus‐host chemotherapy in these patients. In addition, the effect of radiation on the pulmonary vasculature and thoracic volume may render lung transplantation difficult or even impossible.

Strengths and Limitations {#jah32156-sec-0013}
-------------------------

The present study had the following strengths and limitations. It was a large observational retrospective study conducted at a tertiary care referral center, which may have lent some degree of referral bias. The current control group represents a fraction of all SAVRs performed in our institution during the same time frame. While we attempted a thorough matching process, it is not possible to control for a history, occult presence, or severity of the specific malignancies, and, as such, it may be difficult to separate the effect of radiotherapy from the effect of malignancy. However, the majority of malignancies occurred decades ago and none of the patients had any evidence of a recurrent malignancy at the time of their SAVR. In addition, we were not able to match for all baseline comorbidities, which might have accounted for some differences in outcomes. However, the STS score was similar in both groups. The results of the current study should not be generalized to patients receiving localized radiation (eg, isolated peripheral lung/breast lesions) using modern radiation oncology protocols, who may have better outcomes following open surgical repair than the current population. Precise data on the total radiation dose, volume of the heart irradiated, and chemotherapy regimen, which influences outcomes in patients with radiation‐associated AS, was lacking, as most of the patients had these therapies years (and in some cases decades) before development and recognition of severe AS. We did not report frailty index[30](#jah32156-bib-0030){ref-type="ref"} in the current study as the various components of this index were not uniformly recorded at the time these patients were evaluated. However, all patients were deemed appropriate to undergo cardiac surgery after a thorough clinical evaluation by cardiology and cardiothoracic surgery. As a surrogate for frailty, we did report Charlson comorbidity index.[9](#jah32156-bib-0009){ref-type="ref"} A previous report demonstrated a strong association between these 2 indices in older hospitalized patients.[31](#jah32156-bib-0031){ref-type="ref"} Low‐dose dobutamine echocardiography to assess contractile reserve was not uniformly performed in the earlier part of this study, and hence the results are not reported. We chose all‐cause mortality because it is considered to be more objective than cardiac mortality.[32](#jah32156-bib-0032){ref-type="ref"} Data on cancer recurrence during follow‐up (at the site of radiation or a remote site) were not uniformly available.

Conclusions {#jah32156-sec-0014}
===========

In patients with symptomatic severe AS undergoing SAVR, we demonstrate that patients with radiation‐associated severe AS have significantly worse longer‐term survival rates versus an age‐ and sex‐matched comparison group undergoing similar procedures. Mediastinal XRT exposure was associated with worse longer‐term survival across all major subgroups separated based on median age, sex, normal versus abnormal LV‐SVI, median STS score, CAD, or redo cardiac surgery status. The current data require additional validation and raise the question of the possibility of considering alternative management strategies in this population.
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